Recent Investment Analysts’ Ratings Updates for Alphatec (ATEC)

Several brokerages have updated their recommendations and price targets on shares of Alphatec (NASDAQ: ATEC) in the last few weeks:

• 5/7/2026 – Alphatec had its price target lowered by Barclays PLC from $27.00 to $24.00. They now have an “overweight” rating on the stock.
• 5/7/2026 – Alphatec had its price target lowered by Wells Fargo & Company from $28.00 to $14.00. They now have an “overweight” rating on the stock.
• 5/7/2026 – Alphatec had its “buy” rating reaffirmed by HC Wainwright. They now have a $24.00 price target on the stock.
• 5/6/2026 – Alphatec was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/6/2026 – Alphatec had its “buy” rating reaffirmed by Lake Street Capital. They now have a $15.00 price target on the stock.
• 5/6/2026 – Alphatec had its price target lowered by Canaccord Genuity Group Inc. from $25.00 to $23.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Alphatec had its “overweight” rating reaffirmed by Piper Sandler. They now have a $14.00 price target on the stock, down from $25.00.
• 5/6/2026 – Alphatec was given a new $24.00 price target by Barclays PLC. They now have an “overweight” rating on the stock.
• 5/6/2026 – Alphatec had its price target lowered by JPMorgan Chase & Co. from $24.00 to $16.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Alphatec had its price target lowered by TD Cowen from $20.00 to $11.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Alphatec had its price target lowered by Needham & Company LLC from $25.00 to $14.00. They now have a “buy” rating on the stock.
• 3/27/2026 – Alphatec had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Alphatec

In other Alphatec news, COO Scott Lish sold 260,535 shares of Alphatec stock in a transaction on Friday, March 13th. The shares were sold at an average price of $12.30, for a total transaction of $3,204,580.50. Following the sale, the chief operating officer owned 815,704 shares of the company’s stock, valued at $10,033,159.20. The trade was a 24.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David Sponsel sold 163,452 shares of Alphatec stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $12.52, for a total transaction of $2,046,419.04. Following the sale, the executive vice president directly owned 504,932 shares in the company, valued at approximately $6,321,748.64. This trade represents a 24.45% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 629,189 shares of company stock worth $7,801,589. Company insiders own 13.48% of the company’s stock.

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.